Manufacturing News and Research

RSS

Manufacturing is the production of products across all industries, on a large-scale, using machinery.

Opexa 2011 net loss increases to $5,968,448

Opexa Therapeutics, Inc., a biotechnology company developing a novel T-cell therapy for multiple sclerosis (MS), today reported financial results for the year ended December 31, 2011 and provided an overview of corporate developments during the last year.

27 Feb 2012

AB SCIEX granted ISO 13485 certification for quality management system.

AB SCIEX, a global leader in life science analytical technologies, today announced that it has achieved ISO 13485 certification for its quality management system. ISO 13485 is an international standard that requires a manufacturer to demonstrate a comprehensive and compliant quality management system suitable for the design and manufacturing of medical devices.

27 Feb 2012

Rhei granted marketing approval for MuGard in China

ACCESS PHARMACEUTICALS, INC., a biopharmaceutical company leveraging its proprietary drug-delivery platforms to develop treatments in areas of oncology, diabetes, and RNAi, announced that its MuGard partner in China, Rhei Pharmaceuticals HK Ltd., received regulatory and marketing approval for MuGard in China from the State Food and Drug Administration, or SFDA, to treat oral mucositis in cancer patients.

24 Feb 2012

Standard Register fourth quarter revenue decreases to $161.4M

Standard Register today announced its financial results for the fourth quarter and full year 2011. The Company reported revenue of $161.4 million and a net loss of $95.5 million, or $3.28 per diluted share for the fourth quarter of 2011.

24 Feb 2012

Endo fourth quarter total revenues increase 57% to $803.4 million

Endo Pharmaceuticals today reported financial results for the fourth quarter of 2011.

24 Feb 2012

Sandvik reaches agreement with Orchid to sell medical solutions unit

Sandvik has reached an agreement with Orchid Orthopedic Solutions (Orchid), owned by Altor Fund III, to divest Sandvik Medical Solutions, a unit within the Sandvik Venture business area with contract manufacturing of medical implants and instruments for orthopaedic and dental applications.

24 Feb 2012

FSU receives NIH grant to better understand and diagnose dyslexia

If you can read this sentence with ease, consider yourself fortunate: Millions of Americans with dyslexia cannot. In the hope of improving the lives of those struggling readers, a team of experts at Florida State University is working to better understand and diagnose dyslexia and other learning disabilities with a new, $8.5 million grant from the National Institutes of Health.

23 Feb 2012

USPTO rejects MonoSol's patent infringement claims against BDSI

The United States Patent & Trademark Office has informed BioDelivery Sciences International, Inc. that it has rejected all claims by MonoSol Rx, LLC (MonoSol) in its US Patent No. 7,425,292 (the '292 Patent) which is currently being asserted against BDSI and its commercial partners for ONSOLIS.

23 Feb 2012

Actelion, Auxilium partner to develop and commercialize XIAFLEX

Auxilium Pharmaceuticals, Inc. and Actelion Pharmaceuticals Ltd. announced today that they have entered into a long-term partnership for the development, supply and commercialization of XIAFLEX (collagenase clostridium histolyticum), a novel, first-in-class biologic for the potential treatment of Dupuytren's contracture and Peyronie's disease.

23 Feb 2012

Onyx reports total operating revenue of $237.0M for fourth quarter 2011

Onyx Pharmaceuticals, Inc. today reported its financial results for the full year and fourth quarter 2011. Onyx reported non-GAAP net income of $42.0 million, or $0.66 per diluted share, for the full year 2011 compared to non-GAAP net income of $39.2 million, or $0.63 per diluted share, for the same period in 2010.

23 Feb 2012

Allergan's cell-based assay for botulinum toxin type A products receives positive opinions

Allergan is pleased to announce the company has received two positive opinions regarding its fully in vitro, cell-based assay for use in the stability and potency testing of BOTOX and VISTABEL (Allergan's botulinum toxin type A products).

23 Feb 2012

Dyax fourth quarter total revenues decrease to $8.5 million

Dyax Corp. today announced financial results for the fourth quarter and year ended December 31, 2011.

22 Feb 2012

Making a medicinewise choice between brands

Following reports the first generic version of atorvastatin will be hitting pharmacy shelves this week, NPS is urging consumers to be medicinewise when making a choice between medicine brands.

22 Feb 2012

Study aims to achieve early detection of heart disease

With the month of February designated as Heart Health Month, physician-researchers in the Division of Cardiology at the Los Angeles Biomedical Research Institute (LA BioMed) - Dr. Matthew Budoff and Dr. Ronald Oudiz - continue to pave the way with their efforts to develop treatments and therapies for conditions affecting the heart, and to help improve overall heart health.

22 Feb 2012

FDA approves APP's preservative-free Methotrexate Injection

APP Pharmaceuticals, Inc., a wholly owned subsidiary of Fresenius Kabi Pharmaceuticals Holding, Inc., announced today that it has received approval from the U.S. Food and Drug Administration (FDA) to market preservative-free Methotrexate Injection, USP. APP currently manufactures Methotrexate Injection with preservative.

22 Feb 2012

University of Pennsylvania, IMUC enter license agreement for dendritic-cell production method

ImmunoCellular Therapeutics today announced that it has entered into an agreement with the University of Pennsylvania under which University of Pennsylvania has granted the Company an exclusive, worldwide license for a patent pending technology for the production of high-activity dendritic cells.

21 Feb 2012

Xencor, Boehringer Ingelheim partner to develop and supply biosuperior monoclonal antibodies

Xencor, Inc., a company using its proprietary Protein Design Automation (PDA) platform technology to engineer next-generation antibodies, and Boehringer Ingelheim announced today a collaboration agreement for certain Xencor biosuperior monoclonal antibodies.

21 Feb 2012

Cadila Pharmaceuticals to distribute Bactiguard products throughout India

Bactiguard has signed an exclusive co-operation with Cadila Pharmaceuticals, one of the largest healthcare manufacturing groups in India. A signing process will take place at the Swedish Ambassador's residency tonight.

21 Feb 2012

Zhejiang Hisun Pharmaceutical, Pfizer sign framework agreement

Pfizer Inc. and Zhejiang Hisun Pharmaceutical, a leading pharmaceutical company in China, today signed a framework agreement, advancing their previously announced memorandum of understanding (MOU) to establish a joint venture to develop, manufacture and commercialize off-patent pharmaceutical products in China and global markets.

18 Feb 2012

SAP ICC certifies integration of ValGenesis Suite 2.5 with NetWeaver platform

ValGenesis, Inc., a world-class provider of Validation Lifecycle Management Systems (VLMS), announced today that its innovative ValGenesis Suite 2.5 has achieved SAP certification as powered by the SAP NetWeaver technology platform. Attaining this certified integration status deepens ValGenesis' active and on-going commitment to SAP® solutions.

18 Feb 2012